Literature DB >> 24262877

Pelvic exenteration: impact of age on surgical and oncologic outcomes.

Marilyn Huang1, David A Iglesias2, Shannon N Westin2, Bryan Fellman3, Diana Urbauer3, Kathleen M Schmeler2, Michael Frumovitz2, Pedro T Ramirez2, Pamela T Soliman4.   

Abstract

OBJECTIVE: To evaluate whether preoperative age impacts surgical outcomes, complication rates, and/or recurrence in women undergoing pelvic exenteration.
METHODS: All women who underwent a pelvic exenteration for any gynecologic indication at our institution from 1993 to 2010 were included. Women were stratified into groups based on age in years (young: ≤ 50, middle: 51-64, and senior: ≥ 65). Baseline characteristics, surgical outcomes, early (<60 days) and late (≥ 60 days) postoperative complications, and recurrence/survival outcomes were ascertained. Fisher's exact test or Kruskal-Wallis test was performed. Kaplan-Meier survival curves were compared.
RESULTS: 161 patients were included (58 young, 62 in the middle, and 41 senior). Women in the young group predominately had a diagnosis of cervical cancer (82.8%) while women in the senior group primarily had a diagnosis of vulvar or vaginal cancer (70.7%). Senior women were also more likely to have hypertension (p < 0.0001) and pulmonary disease (p = 0.040). Operative time was significantly shorter for women in the senior group (8.5h) compared with the middle (9.5h) and young group (10.1h) (p = 0.0089). There were no significant differences in early or late complications when stratified by age. The overall survival did not differ between age groups (p = 0.3760).
CONCLUSION: Although hypertension and pulmonary disease were more frequent in the senior age group, duration of surgery, blood loss, length of hospital stay and complication rates did not increase with age. Advanced chronological age should not be considered a contraindication to a potentially curative surgical procedure.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Age; Gynecologic cancer; Pelvic exenteration

Mesh:

Year:  2013        PMID: 24262877      PMCID: PMC3936604          DOI: 10.1016/j.ygyno.2013.11.014

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  10 in total

1.  Gynecologic cancer in the very elderly.

Authors:  A W Kennedy; J S Flagg; K D Webster
Journal:  Gynecol Oncol       Date:  1989-01       Impact factor: 5.482

2.  Pelvic exenteration in gynecologic oncology: a single institution study over 20 years.

Authors:  T Benn; R A Brooks; Q Zhang; M A Powell; P H Thaker; D G Mutch; I Zighelboim
Journal:  Gynecol Oncol       Date:  2011-03-27       Impact factor: 5.482

3.  Predictors for long-term survival after interdisciplinary salvage surgery for advanced or recurrent gynecologic cancers.

Authors:  M C Fleisch; P Pantke; M W Beckmann; H G Schnuerch; R Ackermann; M O Grimm; H G Bender; P Dall
Journal:  J Surg Oncol       Date:  2007-05-01       Impact factor: 3.454

4.  Pelvic exenterations for gynecological malignancies: twenty-year experience at Roswell Park Cancer Institute.

Authors:  S Sharma; K Odunsi; D Driscoll; S Lele
Journal:  Int J Gynecol Cancer       Date:  2005 May-Jun       Impact factor: 3.437

5.  Pelvic exenteration in the elderly patient.

Authors:  C M Matthews; M Morris; T W Burke; D M Gershenson; J T Wharton; F N Rutledge
Journal:  Obstet Gynecol       Date:  1992-05       Impact factor: 7.661

6.  Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA.

Authors:  Jonathan S Berek; Candace Howe; Leo D Lagasse; Neville F Hacker
Journal:  Gynecol Oncol       Date:  2005-10       Impact factor: 5.482

7.  Long-term clinical outcome of pelvic exenteration in patients with advanced gynecological malignancies.

Authors:  Christina Fotopoulou; Ulf Neumann; Robert Kraetschell; Joerg C Schefold; Henning Weidemann; Werner Lichtenegger; Jalid Sehouli
Journal:  J Surg Oncol       Date:  2010-05-01       Impact factor: 3.454

8.  Primary radical surgery in elderly patients with epithelial ovarian cancer: analysis of surgical outcome and long-term survival.

Authors:  Christina Fotopoulou; Konstantinos Savvatis; Elisabeth Steinhagen-Thiessen; Marcus Bahra; Werner Lichtenegger; Jalid Sehouli
Journal:  Int J Gynecol Cancer       Date:  2010-01       Impact factor: 3.437

9.  Total laparoscopic hysterectomy for oncological indications with outcomes stratified by age.

Authors:  Katherine A O'Hanlan; Gloria Shining Huang; Lisbeth Lopez; Anne-Caroline Garnier
Journal:  Gynecol Oncol       Date:  2004-10       Impact factor: 5.482

10.  Pelvic exenteration: ten-year experience at the European Institute of Oncology in Milan.

Authors:  Angelo Maggioni; Giovanni Roviglione; Fabio Landoni; Vanna Zanagnolo; Michele Peiretti; Nicoletta Colombo; Luca Bocciolone; Roberto Biffi; Lucas Minig; C Paul Morrow
Journal:  Gynecol Oncol       Date:  2009-05-02       Impact factor: 5.482

  10 in total
  4 in total

1.  Hospital surgical volume and perioperative mortality of pelvic exenteration for gynecologic malignancies.

Authors:  Koji Matsuo; Shinya Matsuzaki; Rachel S Mandelbaum; Kazuhide Matsushima; Maximilian Klar; Brendan H Grubbs; Lynda D Roman; Jason D Wright
Journal:  J Surg Oncol       Date:  2019-11-19       Impact factor: 3.454

2.  The Impact of the Preoperative Status on the Short-term Outcomes After Exenteration and Pelvic Reconstruction.

Authors:  Nicolae Bacalbasa; Irina Balescu; Mihaela Vilcu; Simona Dima; Iulian Brezean
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

3.  Factors affecting hospital length of stay following pelvic exenteration surgery.

Authors:  Ying Guo; Eugene Chang; Mehtap Bozkurt; Minjeong Park; Diane Liu; Jack B Fu
Journal:  J Surg Oncol       Date:  2017-10-16       Impact factor: 3.454

Review 4.  Malignant transformation of vaginal adenosis to clear cell carcinoma without prenatal diethylstilbestrol exposure: a case report and literature review.

Authors:  Lihong Pang; Lei Li; Lan Zhu; Jinghe Lang; Yalan Bi
Journal:  BMC Cancer       Date:  2019-08-13       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.